The long-term airway anti-inflammatory effect of fix-dosed maintenance therapy with budesonide/formoterol combination inhaler in comparison with salmeterol/fluticasone.

The long-term airway anti-inflammatory effect of fix-dosed maintenance therapy with budesonide/formoterol combination inhaler in comparison with salmeterol/fluticasone. - Long-term anti-inflammatory effect of BUD/FM inhaler

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010151

Enrollment

100

Registered

2013-03-03

Start date

2011-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

Budesonide/formoterol(BUD/FM) group SAlmeterol/fluticasone (SFC) group BUD/FM to SFC group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The asthmatics treated for at least 6 months with SFC250 2 puffs/day treatment in whom well-controlled status were maintained

Exclusion criteria

Exclusion criteria: Current smokers, those who had a smoking history (smoking index > 400) and patients with suspected COPD were excluded

Design outcomes

Primary

Measure	Time frame
FeNO, as a marker of airway inflammation	—

Secondary

Measure	Time frame
asthma control test (ACT) score, the number of SABA use and the adherence rate to the treatment	—

Countries

Japan

Contacts

Public ContactMasayuki Hojo

National Center for Global Health and Medicine Devision of Respiratory Medicine

mhojo@hosp.ncgm.go.jp03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026